T. Bonaventura

发表

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

V. Gebski, I. Vergote, C. Marth, 2012, British Journal of Cancer.

Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

L. Kritharides, J. Vardy, D. Ngo, 2020, Journal of clinical medicine.

Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.

P. Beale, F. Amant, L. Mileshkin, 2019, Gynecologic oncology.

Letrozole (FEMARA®), a new potent, selective aromatase inhibitor (AI): Superior to another AI, aminoglutethimlde (AG), in postmenopausal women with advanced breast cancer (ABC), after relapse or progression on previous anti-estrogen therapy

D. Campos, K. Possinger, T. Bonaventura, 1997 .

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Kylie L. Gorringe, S. Fox, P. Fasching, 2020, Modern Pathology.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, K. Byth, S. Lade, 2018, Nature Communications.

A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.

N. Bradshaw, M. Friedlander, Susana Banerjee, 2021, Gynecologic oncology.

Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.

J. Denham, T. Shakespeare, Jarad Martin, 2017, International journal of radiation oncology, biology, physics.

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.

A. deFazio, P. Beale, F. Amant, 2019, Gynecologic oncology.

PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression

A. deFazio, P. Beale, F. Amant, 2019, Journal of gynecologic oncology.

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

K. Byth, S. Fox, S. Lade, 2014, Scientific Reports.

Business as unusual: medical oncology services adapt and deliver during COVID‐19

C. Gedye, G. Blanchard, A. van der Westhuizen, 2021, Internal medicine journal.

Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial

C. Friedenreich, K. Courneya, D. Tu, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Current Care And Needs Of Adult Cancer Survivors-A Cross-sectional Survey Asia Pacific

M. Friedlander, D. Goldstein, K. Webber, 2012 .

Implications of a needs assessment intervention for people with progressive cancer: Impact on clinical assessment, response and service utilisation

D. Sibbritt, D. Currow, A. Girgis, 2012, Psycho-oncology.

Phase II study of anastrozole in recurrent estrogen (ER) / progesterone (PR) positive endometrial cancer: The PARAGON trial—ANZGOG 0903.

P. Beale, L. Mileshkin, M. Friedlander, 2016 .

Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.

J. Denham, T. Shakespeare, Jarad Martin, 2017, International journal of radiation oncology, biology, physics.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, S. Lade, N. Traficante, 2018, Nature Communications.